Chicago—The controversy swirling around the appropriateness of screening for prostate cancer may have become even more controversial.
At the annual meeting of the American Urological Association (AUA), held here in April, the association released an updated “best practice” statement that calls for offering early detection of and risk assessment for prostate cancer to all asymptomatic men at age 40 years with an estimated life expectancy of more than 10 years. This process would involve determining a baseline prostate-specific antigen (PSA) level to help physicians and patients develop a strategy for monitoring prostate cancer risk. Depending on the baseline reading, such a strategy might involve annual PSA testing and digital rectal examination (DRE) or more infrequent testing (http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-reports/psa09.pdf).
Graphic Jump Location
Controversy surrounding the appropriateness of prostate cancer screening for asymptomatic men is reflected in the wide divergence of recommendations for such testing by policy-making groups.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 2
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.